Pushpamali De Silva, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphocytes, Tumor-Infiltrating | 6 | 2021 | 1104 | 0.930 |
Why?
|
| Forkhead Transcription Factors | 2 | 2018 | 1623 | 0.450 |
Why?
|
| Immunotherapy | 6 | 2021 | 4746 | 0.450 |
Why?
|
| Repressor Proteins | 2 | 2018 | 2969 | 0.350 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 2823 | 0.340 |
Why?
|
| Breast Neoplasms | 7 | 2021 | 21069 | 0.240 |
Why?
|
| Photochemotherapy | 2 | 2022 | 826 | 0.240 |
Why?
|
| Keratosis, Actinic | 1 | 2022 | 71 | 0.190 |
Why?
|
| Lymphocyte Subsets | 2 | 2019 | 313 | 0.180 |
Why?
|
| Neoplasms | 5 | 2020 | 22340 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2020 | 8603 | 0.160 |
Why?
|
| Calcitriol | 1 | 2020 | 299 | 0.150 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2019 | 152 | 0.150 |
Why?
|
| Immunity | 2 | 2022 | 1000 | 0.150 |
Why?
|
| Receptors, Calcitriol | 1 | 2020 | 361 | 0.140 |
Why?
|
| Th1 Cells | 1 | 2021 | 1040 | 0.130 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 1527 | 0.130 |
Why?
|
| Genes, BRCA2 | 1 | 2019 | 591 | 0.130 |
Why?
|
| Genes, BRCA1 | 1 | 2019 | 753 | 0.120 |
Why?
|
| Myocarditis | 1 | 2022 | 803 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 6101 | 0.120 |
Why?
|
| Receptors, Estrogen | 2 | 2021 | 2242 | 0.110 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2016 | 526 | 0.100 |
Why?
|
| Cytological Techniques | 1 | 2014 | 217 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2019 | 4130 | 0.100 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2019 | 1812 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 1885 | 0.090 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 3213 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 4555 | 0.080 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2020 | 1759 | 0.080 |
Why?
|
| Cytokines | 2 | 2022 | 7417 | 0.070 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 1643 | 0.070 |
Why?
|
| Cell Movement | 1 | 2018 | 5190 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 8522 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2018 | 10086 | 0.060 |
Why?
|
| Breast | 1 | 2014 | 1950 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 4405 | 0.060 |
Why?
|
| Prognosis | 3 | 2021 | 29890 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 9373 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 5450 | 0.050 |
Why?
|
| Aminolevulinic Acid | 1 | 2022 | 147 | 0.050 |
Why?
|
| Receptors, CXCR5 | 1 | 2021 | 88 | 0.050 |
Why?
|
| Humans | 18 | 2022 | 765926 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2021 | 271 | 0.040 |
Why?
|
| Receptors, CXCR | 1 | 2020 | 52 | 0.040 |
Why?
|
| Aging | 1 | 2019 | 8725 | 0.040 |
Why?
|
| Photosensitizing Agents | 1 | 2022 | 626 | 0.040 |
Why?
|
| Chemokine CXCL12 | 1 | 2020 | 455 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2019 | 302 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2019 | 245 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2022 | 1648 | 0.040 |
Why?
|
| Female | 10 | 2021 | 396141 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 13631 | 0.030 |
Why?
|
| Animals | 4 | 2022 | 168735 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 733 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2021 | 1152 | 0.030 |
Why?
|
| Dermatologic Agents | 1 | 2020 | 314 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2019 | 548 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2020 | 729 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 11196 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2021 | 1404 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2022 | 1995 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2022 | 2114 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2020 | 3608 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2016 | 1865 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 3604 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2019 | 2925 | 0.020 |
Why?
|
| Leukocytes | 1 | 2016 | 2027 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2016 | 2920 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 3940 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 3111 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 4641 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2016 | 2570 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 14643 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 5500 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 5784 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 15401 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2021 | 7847 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2020 | 10426 | 0.010 |
Why?
|
| Mice | 2 | 2022 | 81782 | 0.010 |
Why?
|
| Prevalence | 1 | 2021 | 15828 | 0.010 |
Why?
|
| Gene Expression | 1 | 2016 | 7581 | 0.010 |
Why?
|
| Apoptosis | 1 | 2020 | 9505 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2019 | 12768 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 8037 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 3816 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 18292 | 0.010 |
Why?
|
| Cell Line | 1 | 2016 | 15540 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2016 | 4424 | 0.010 |
Why?
|
| Middle Aged | 3 | 2021 | 223016 | 0.010 |
Why?
|
| Adult | 3 | 2021 | 223088 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 11895 | 0.010 |
Why?
|
| Phenotype | 1 | 2016 | 16714 | 0.010 |
Why?
|
| Male | 3 | 2021 | 363815 | 0.010 |
Why?
|
| Aged | 2 | 2021 | 171163 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2022 | 36547 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 59496 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 65194 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 59857 | 0.010 |
Why?
|